AlzChem Group AG

Informe acción XTRA:ACT

Capitalización de mercado: €450.8m

AlzChem Group Resultados de beneficios anteriores

Pasado controles de criterios 6/6

AlzChem Group ha aumentado sus beneficios a una tasa media anual de 15%, mientras que los beneficios de la industria de Chemicals han experimentado un crecimiento de 11% anual. Los ingresos han ido creciendo a una tasa media de 9.8% al año. La rentabilidad financiera de AlzChem Group es de 22%, y sus márgenes netos son de 7.2%.

Información clave

17.5%

Tasa de crecimiento de los beneficios

17.5%

Tasa de crecimiento del BPA

Crecimiento de la industria Chemicals 12.4%
Tasa de crecimiento de los ingresos9.8%
Rentabilidad financiera25.5%
Margen neto8.3%
Próxima actualización de resultados07 Nov 2024

Actualizaciones de resultados anteriores recientes

AlzChem Group's (ETR:ACT) Earnings Seem To Be Promising

May 08
AlzChem Group's (ETR:ACT) Earnings Seem To Be Promising

Recent updates

AlzChem Group (ETR:ACT) Has A Pretty Healthy Balance Sheet

Sep 07
AlzChem Group (ETR:ACT) Has A Pretty Healthy Balance Sheet

A Look At The Intrinsic Value Of AlzChem Group AG (ETR:ACT)

Jun 04
A Look At The Intrinsic Value Of AlzChem Group AG (ETR:ACT)

AlzChem Group's (ETR:ACT) Earnings Seem To Be Promising

May 08
AlzChem Group's (ETR:ACT) Earnings Seem To Be Promising

Shareholders Will Probably Hold Off On Increasing AlzChem Group AG's (ETR:ACT) CEO Compensation For The Time Being

May 01
Shareholders Will Probably Hold Off On Increasing AlzChem Group AG's (ETR:ACT) CEO Compensation For The Time Being

AlzChem Group's (ETR:ACT) Upcoming Dividend Will Be Larger Than Last Year's

Apr 26
AlzChem Group's (ETR:ACT) Upcoming Dividend Will Be Larger Than Last Year's

Is AlzChem Group (ETR:ACT) A Risky Investment?

Apr 11
Is AlzChem Group (ETR:ACT) A Risky Investment?

AlzChem Group's (ETR:ACT) Dividend Will Be Increased To €1.20

Mar 29
AlzChem Group's (ETR:ACT) Dividend Will Be Increased To €1.20

The Market Lifts AlzChem Group AG (ETR:ACT) Shares 26% But It Can Do More

Mar 07
The Market Lifts AlzChem Group AG (ETR:ACT) Shares 26% But It Can Do More

Why AlzChem Group AG (ETR:ACT) Could Be Worth Watching

Nov 01
Why AlzChem Group AG (ETR:ACT) Could Be Worth Watching

Is There An Opportunity With AlzChem Group AG's (ETR:ACT) 42% Undervaluation?

Oct 12
Is There An Opportunity With AlzChem Group AG's (ETR:ACT) 42% Undervaluation?

AlzChem Group (ETR:ACT) Is Increasing Its Dividend To €1.05

May 06
AlzChem Group (ETR:ACT) Is Increasing Its Dividend To €1.05

AlzChem Group AG's (ETR:ACT) CEO Compensation Is Looking A Bit Stretched At The Moment

May 05
AlzChem Group AG's (ETR:ACT) CEO Compensation Is Looking A Bit Stretched At The Moment

AlzChem Group (ETR:ACT) Will Pay A Larger Dividend Than Last Year At €1.05

Apr 05
AlzChem Group (ETR:ACT) Will Pay A Larger Dividend Than Last Year At €1.05

AlzChem Group (ETR:ACT) Is Increasing Its Dividend To €1.05

Mar 04
AlzChem Group (ETR:ACT) Is Increasing Its Dividend To €1.05

AlzChem Group (ETR:ACT) Is Paying Out A Larger Dividend Than Last Year

Apr 24
AlzChem Group (ETR:ACT) Is Paying Out A Larger Dividend Than Last Year

AlzChem Group's (ETR:ACT) Dividend Will Be Increased To €1.00

Mar 29
AlzChem Group's (ETR:ACT) Dividend Will Be Increased To €1.00

AlzChem Group (ETR:ACT) Has Announced That It Will Be Increasing Its Dividend To €1.00

Feb 27
AlzChem Group (ETR:ACT) Has Announced That It Will Be Increasing Its Dividend To €1.00

AlzChem Group (ETR:ACT) Posted Healthy Earnings But There Are Some Other Factors To Be Aware Of

Nov 23
AlzChem Group (ETR:ACT) Posted Healthy Earnings But There Are Some Other Factors To Be Aware Of

Are Investors Undervaluing AlzChem Group AG (ETR:ACT) By 46%?

Jun 10
Are Investors Undervaluing AlzChem Group AG (ETR:ACT) By 46%?

At €24.50, Is AlzChem Group AG (ETR:ACT) Worth Looking At Closely?

Apr 07
At €24.50, Is AlzChem Group AG (ETR:ACT) Worth Looking At Closely?

AlzChem Group AG (ETR:ACT) Is Yielding 3.0% - But Is It A Buy?

Mar 23
AlzChem Group AG (ETR:ACT) Is Yielding 3.0% - But Is It A Buy?

AlzChem Group AG's (ETR:ACT) Intrinsic Value Is Potentially 32% Above Its Share Price

Mar 10
AlzChem Group AG's (ETR:ACT) Intrinsic Value Is Potentially 32% Above Its Share Price

Is AlzChem Group AG's (ETR:ACT) Recent Stock Performance Influenced By Its Fundamentals In Any Way?

Feb 24
Is AlzChem Group AG's (ETR:ACT) Recent Stock Performance Influenced By Its Fundamentals In Any Way?

Our Take On The Returns On Capital At AlzChem Group (ETR:ACT)

Feb 11
Our Take On The Returns On Capital At AlzChem Group (ETR:ACT)

Update: AlzChem Group (ETR:ACT) Stock Gained 13% In The Last Year

Aug 07
Update: AlzChem Group (ETR:ACT) Stock Gained 13% In The Last Year

Is Now An Opportune Moment To Examine AlzChem Group AG (ETR:ACT)?

Jul 20
Is Now An Opportune Moment To Examine AlzChem Group AG (ETR:ACT)?

Does This Valuation Of AlzChem Group AG (ETR:ACT) Imply Investors Are Overpaying?

Jul 03
Does This Valuation Of AlzChem Group AG (ETR:ACT) Imply Investors Are Overpaying?

Desglose de ingresos y gastos

Cómo gana y gasta dinero AlzChem Group. Basado en los últimos beneficios reportados, en base a los últimos doce meses (LTM).


Historial de beneficios e ingresos

XTRA:ACT Ingresos, gastos y beneficios (EUR Millions)
FechaIngresosBeneficiosGastos G+AGastos de I+D
30 Jun 24557461610
31 Mar 24546391550
31 Dec 23546351490
30 Sep 23528301450
30 Jun 23549281410
31 Mar 23570301400
31 Dec 22550301390
30 Sep 22534291360
30 Jun 22487281350
31 Mar 22454271340
31 Dec 21429281330
30 Sep 21420271350
30 Jun 21406261330
31 Mar 21397231290
31 Dec 20386201290
30 Sep 20370161270
30 Jun 20389171270
31 Mar 20387171270
31 Dec 19385181250
30 Sep 19389191240
30 Jun 19380181220
31 Mar 19380201200
31 Dec 18383231180
30 Sep 18380221140
30 Jun 18398321230
31 Mar 18364211150
31 Dec 17361201140
30 Sep 17356221150
31 Dec 16333151110
30 Sep 16331121080
31 Dec 15329151060
31 Dec 1429814980
31 Dec 1330217930

Ingresos de calidad: ACT tiene ganancias de alta calidad.

Margen de beneficios creciente: Los actuales márgenes de beneficio (6.3%) de ACT son superiores a los del año pasado (5.5%).


Análisis del flujo de caja libre vs. Beneficios


Análisis del crecimiento de los beneficios en el pasado

Tendencia de beneficios: Los beneficios de ACT han crecido un 12.6% al año en los últimos 5 años.

Acelerando crecimiento: El crecimiento de los beneficios de ACT en el último año (30.4%) supera su media de 5 años (15% al año).

Beneficios vs. Industria: El crecimiento de los beneficios de ACT en el último año (30.4%) superó al de la industria Chemicals -15.1%.


Rentabilidad financiera

Alta ROE: La rentabilidad financiera (22%) de ACT se considera alta.


Rentabilidad económica


Rendimiento del capital invertido


Descubre empresas con buenos resultados en el pasado